Phase II study of erlotinib plus bevacizumab and inserted cisplatin, pemetrexed plus bevacizumab as a 1st-line treatment for advanced non-squamous, non-small cell lung cancer harboring activating EGFR mutations
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Pemetrexed (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Oct 2018 Status changed from active, no longer recruiting to discontinued.
- 21 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Oct 2014 New trial record